Pharmacokinetic study of lenvatinib in Chinese patients with solid tumors
Dan Liu, Lei Liu, Lin Shen, Tomoki Kubota, Takuya Suzuki, Hiroki Ikezawa, Sari Shiba, Yuxian Bai, Dan Liu, Lei Liu, Lin Shen, Tomoki Kubota, Takuya Suzuki, Hiroki Ikezawa, Sari Shiba, Yuxian Bai
Abstract
Aim: To assess the pharmacokinetics of once-daily oral lenvatinib 24 mg in Chinese patients. Material & methods: Patients had any solid tumor (except hepatocellular carcinoma) that was resistant to standard antitumor therapies or for which no appropriate treatment was available. Results: Twelve patients were enrolled. Maximum plasma concentrations of lenvatinib were observed at 2 and 4 h (median) after single and multiple doses (day 15), respectively. Steady state was achieved within 8 days. The geometric mean maximum observed concentration at steady state was 258 ng/ml (coefficient of variance: 49.2%); and the geometric mean area under the concentration-time curve from zero to 24 h at steady state was 3090 ng•h/ml (coefficient of variance: 44.7%). No accumulation was seen after 15 days. Conclusion: Lenvatinib pharmacokinetic data in Chinese patients are consistent with data in multinational trials, supporting usage of the 24-mg dose. Clinical trial registration: NCT03009292 (ClinicalTrials.gov).
Keywords: Chinese ethnicity/race; area under the curve; lenvatinib; pharmacokinetics; solid tumors.
Source: PubMed